Highlights | Oncology | JAMA Oncology | JAMA Network
[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 171
Citations 0
In This Issue of JAMA Oncology
August 2019


JAMA Oncol. 2019;5(8):1081. doi:10.1001/jamaoncol.2018.4773

Poly(adenosine diphosphate-ribose) polymerase inhibitor and anti–programmed death receptor 1 therapy have limited clinical activity for advanced triple-negative breast cancer (TNBC). Vinayak et al conducted a phase 2 study of niraparib plus pembrolizumab to assess its clinical activity and safety in patients with advanced or metastatic TNBC. Results showed more responses in patients with BRCA mutations than in those with wild-type tumors. Odunsi and Pejovic provide an Editorial.

Editorial and Related Article

Some birth defects are strongly associated with childhood cancer, but comprehensive evaluation of childhood cancer risk has been limited. Lupo et al performed a multistate, population-based, registry linkage study to identify birth defect–childhood cancer associations. Results showed that the number of birth defects diagnosed was directly associated with cancer risk in children with nonchromosomal birth defects. These findings may guide cancer screening in children with birth defects. Spector and Olshan provide an Editorial.